Therefore, the research and development of afatinib and dacomitinib in HER2-positive breast cancer is still in the exploration stage, and their potential may lie in combined therapy or precise application in patients with specific molecular phenotypes. This evidence concerns the gene ERBB2 and breast carcinoma.